Status:
COMPLETED
SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adolescent and adult patients with persistent asthma.
Eligibility Criteria
Inclusion
- Minimum of 3 months documented history of asthma, diagnosed according to the American Thoracic Society (ATS) definition.
- Prescribed inhaled GCS at a dose of ≥320 µg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
Exclusion
- Use of any b-blocking agent, including eye-drops.
- Use of oral GCS as maintenance treatment.
- Known or suspected hypersensitivity to study therapy or excipients.
- A history of smoking ≥ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00290264
Start Date
December 1 2004
End Date
August 1 2006
Last Update
January 24 2011
Active Locations (209)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalst, Belgium
2
Research Site
Aartrijke, Belgium
3
Research Site
Alsemberg, Belgium
4
Research Site
Anderlecht, Belgium